Close Menu

NEW YORK ─ The US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has awarded $13 million to Siemens Healthineers for the development of its Advia Centaur SARS-CoV-2 antibody test and high-throughput Atellica IM SARS-CoV-2 Antigen (CoV2Ag) Test, BARDA announced on Friday.

Siemens Healthineers' CoV2Ag test is a chemiluminescent immunoassay in development for the detection of SARS-CoV-2 antigens in nasal swabs or saliva specimens on the firm's Advia Centaur XP and XPT systems, BARDA said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.